Danaher Corporation, USA

Total revenue: $23,890 million

APAC revenue: $7,191 million*

Danaher operates over 15 companies in the biotechnology, life sciences, and diagnostics sectors, divided into three segments: Biotechnology, Life Sciences, and Diagnostics. Biotechnology includes the Pall Life Sciences business  and Cytiva. The Life Sciences segment includes Abcam, Aldevron, Beckman Coulter, IDT, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and SCIEX. The Diagnostics segment features brands such as Beckman Coulter, Cepheid, HemoCue, Leica Biosystems, Mammotome, and Radiometer, with manufacturing across North America, Europe, Asia, and Australia. 

Total revenue reached $23,890 million. Biotechnology generated $7,172 million, with contributions of $2,454 million from North America, $2,407 million from Western Europe, $329 million from Other Developed Markets, and $1,982 million from High-Growth Markets. The Life Sciences segment brought in $7,141 million, including $2,999 million from North America, $1,519 million from Western Europe, $510 million from Other Developed Markets, and $2,113 million from High-Growth Markets. Diagnostics accounted for $9,577 million, with $4,508 million from North America, $1,542 million from Western Europe, $431 million from Other Developed Markets, and $3,096 million from High-Growth Markets.

*‘’(Company defines its geographical segments as follows: North America includes the United States and Canada. Other Developed Markets encompass Japan, Australia, and New Zealand. High-Growth Markets refer to developing regions with accelerated growth in GDP and infrastructure, including Eastern Europe, the Middle East, Africa, Latin America (including Mexico), and Asia (excluding Japan, Australia, and New Zealand). Developed Markets comprise all regions not classified as high-growth markets.)

“Over the past five years, we have made several, strategic portfolio moves to strengthen our leading positions in life sciences and diagnostics and accelerate our long-term growth and earnings trajectory. We established our Dental and Environmental & Applied Solutions segments as stand-alone public companies in Envista and Veralto. We largely replaced their revenue contribution through the acquisitions of higher long-term growth and higher margin businesses such as Cytiva, Aldevron and Abcam. Cytiva is the industry’s premier bioprocessing franchise, and the additions of Aldevron and Abcam expanded our footholds in the highly attractive areas of genomics and proteomics. Additionally, demand for respiratory diagnostics has expanded significantly, and Cepheid’s respiratory franchise is more than six times larger today than it was before the COVID-19—a strong position we expect to sustain long-term given Cepheid’s differentiated offering and leading presence at the point-of-care.” 

•  Rainer M. Blair, President and Chief Executive Officer, Danaher Corporation